CEO Alan Shortall says the $3.2M of revenue the company recorded for the period marks "an inflection point." "From here, I expect the slope to be significant," Shortall adds. (PR)
The shares rallied 9.5% during the regular session after the company announced a supply agreement with MedImmune under which UNIS "will supply customized devices from its platform of ReadyToGo wearable injectors."
Although UNIS said it would "generate revenue starting in Q1," other financial terms weren't disclosed. (PR)